Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · IEX Real-Time Price · USD
11.21
+0.31 (2.84%)
At close: May 1, 2024, 4:00 PM
11.15
-0.06 (-0.53%)
After-hours: May 1, 2024, 6:24 PM EDT
Roivant Sciences Revenue
Roivant Sciences had revenue of $123.24M in the twelve months ending December 31, 2023, with 185.76% growth year-over-year. Revenue in the quarter ending December 31, 2023 was $37.14M with 117.80% year-over-year growth. In the fiscal year ending March 31, 2023, Roivant Sciences had annual revenue of $61.28M with 10.84% growth.
Revenue (ttm)
$123.24M
Revenue Growth
+185.76%
P/S Ratio
73.30
Revenue / Employee
$136,329
Employees
904
Market Cap
9.03B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2023 | 61.28M | 5.99M | 10.84% |
| Mar 31, 2022 | 55.29M | 31.49M | 132.34% |
| Mar 31, 2021 | 23.80M | -43.89M | -64.85% |
| Mar 31, 2020 | 67.69M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionROIV News
- 6 days ago - Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis - Business Wire
- 4 weeks ago - Roivant's anti-inflammatory drug succeeds in mid-stage study - Reuters
- 4 weeks ago - Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million - GlobeNewsWire
- 2 months ago - Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update - GlobeNewsWire
- 4 months ago - Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease - GlobeNewsWire
- 4 months ago - Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease - GlobeNewsWire
- 5 months ago - Roivant Sciences shares drop as lupus treatment misses trial goal - Market Watch
- 5 months ago - Roivant Sciences' lupus drug fails to reduce symptoms in mid-stage study - Reuters